Neutral Aurobindo Pharma Ltd Target Rs. 1,500 By Motilal Oswal Financial Services Ltd
Operationally in-line quarter; broad-based growth across segments Efforts under way to resolve regulatory issue/scale up Pen-G production Aurobindo Pharma (ARBP) delivered in-line operational performance in 1QFY25. The robust execution across key markets was partly offset by seasonality and higher remediation costs for the quarter. * We largely maintain our estimates for FY25/FY26. We value ARBP … Read more